Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31242942 | 0.85 | KDM4E (0.63) | KMT2AMEN1ATMALDH1A1LMNA | |
| SCHEMBL316626 | 0.85 | KDM4E (0.63) | KMT2AMEN1ATMALDH1A1LMNA | |
| SCHEMBL13331944 | 0.84 | PARP1 (0.58) | KMT2AMEN1GPR139ATMALDH1A1 | |
| Hydrochloric Acid SCHEMBL15137104 | 0.83 | KDM4E (0.61) | KMT2AMEN1ATMALDH1A1LMNA | |
| SCHEMBL2984329 | 0.82 | KMT2A (0.60) | KMT2AMEN1GPR139ATMALDH1A1 | |
| SCHEMBL15906174 | 0.81 | KMT2A (0.60) | KMT2AMEN1GPR139ATMALDH1A1 | |
| SCHEMBL47363 | 0.80 | CA1 (0.57) | KMT2AMEN1GPR139ALDH1A1CYP1A2 | |
| Cyanide SCHEMBL29178066 | 0.80 | KDM4E (0.58) | KMT2AMEN1ATMALDH1A1LMNA | |
| SCHEMBL7674509 | 0.80 | GAA (0.59) | KMT2AMEN1GPR139SMN1; SMN2MAPT | |
| SCHEMBL8858800 | 0.79 | KMT2A (0.61) | KMT2AMEN1GPR139ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791299-B2 | Compounds for the inhibition of herpes viruses | UNIVERSITE LAVAL (CA) | 2014-07-29 | — | — | US | disclosed |
| US-8791299-B2 | Compounds for the inhibition of herpes viruses | UNIVERSITE LAVAL (CA) | 2014-07-29 | — | — | US | disclosed |
| US-20120157538-A1 | Compounds for the Inhibition of Herpes Viruses | UNIVERSITE LAVAL (CA) | 2012-06-21 | — | — | US | disclosed |
| US-20120157538-A1 | Compounds for the Inhibition of Herpes Viruses | UNIVERSITE LAVAL (CA) | 2012-06-21 | — | — | US | disclosed |
| WO-2010132992-A1 | COMPOUNDS FOR THE INHIBITION OF HERPESVIRUSES | UNIVERSITé LAVAL (CA) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157538-A1 | Compounds for the Inhibition of Herpes Viruses | NOS3, NOS1, DNA2 | KMT2A 523/4885MEN1 1837/4885GPR139 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.